In this study, selenocystine, a nutritionally available selenoamino acid, was identified for the first time as a novel agent with anti proliferative activity on human keloids. The 20 μM concentration after 48 h treatment used here was the most effective to reduce keloid fibroblast growth. We analyzed the gene expression profile of selenocystine treatment response in keloid fibroblasts by the microarray system to characterize the effects of selenocystine on human keloids. The major alterations in keloid fibroblasts following selenocystine exposure included up-regulation of the genes encoding cell death and transcription factors. Prominent down-regulation of genes involved in development, cell adhesion and cytoskeleton, as well as extra cellular matrix genes, usually strongly upregulated in keloids, resulted following selenocystine exposure. The range of the down-regulated genes and the degree of the decreased expression appeared to be correlated with the degree of the morphological alterations in selenocystine treated keloids.
Introduction
Keloids (OMIM 148100) are benign skin tumors occurring during wound healing in genetically predisposed patients. Keloids are characterized by the proliferation of dermal fibroblasts, overproduction of extracellular matrix components (ECM), an increased infiltration of inflammatory cells including lymphocytes, mast cells (MCs) and macrophages. Keloids spread to invade normal skin beyond the boundaries of the original wound and do not regress spontaneously [1] .
Worldwide keloid prevalence varies by geographic ancestry from 0.09% in Great Britain to 16% in the Congo [2] . Although keloid prevalence in the United States is not well documented, they are fairly common in young women and African Americans [3] . Keloids tend to be present, on the face (with cheek and earlobes predominating), upper extremities, chest, presternal area, neck, back, lower extremities and breasts.
Previously, we found that in keloid fibroblasts a p53 (TP53) under expression, due to the sequence mutations, in concert with ΔNp63 (an isoform of the TP63 gene) activation, is central in the mechanism involved in keloid proliferation. Suppression of apoptosis might contribute to keloid development by means of accumulation of continuously proliferating cells whereas the disruption or elimination of genetically altered cells might decrease tumor potential [4] [5] [6] . The exact etiology is still unknown and until today, there is no appropriate treatment yet for keloid disease. It is reasonable to believe that the lack of effective therapies is due to an insufficient understanding of the disease pathology and the lack of an animal model.
Epidemiological studies, preclinical investigations and clinical intervention trials support the role of seleno-compounds as potent cancer chemo-preventive agents [7] especially for several major cancers, including prostate, lung, colon and liver cancers [8, 9] .
Growing evidence suggested that reactive oxygen species (ROS) played an important role in cancer cell apoptosis induced by many anticancer agents. Interestingly, ROS production has been linked to cytotoxicity of selenum compounds [10, 11] . Selenocystine, a nutritionally available seleno-amino acid, was identified as a novel agent with broad-spectrum antitumor activity. Several human cancer cell lines were shown to be susceptible to selenocystine, inducing a dosedependent apoptosis in A375, HepG2 and MCF7 cells. Mechanistic studies showed time-and dose-dependent increases in intracellular reactive oxygen species (ROS) in susceptible cancer cells (MCF7 and HepG2 cells) treated with selenocystine, that was not observed in non-susceptible normal human fibroblast Hs68 cells. ROS has been shown to play a key role in the signaling pathway of selenocystineinduced, DNA damage-mediated apoptosis in susceptible cancer cells [12, 13] .
Despite its potential applications in pharmacology and cancer therapy, limited information is available on the action mechanism of selenocystine.
Since we previously found a significant correlation between ROS generation and apoptosis data, we might hypothesize that ROS could be an upstream mediator for p53 activation in keloid fibroblasts, leading to p53 activation that failed in keloids due to p53 mutations together with Δp63 over-expression [4] [5] [6] .
In this research, we investigated, for the first time, if selenocystine has an anti-proliferative effect on keloid fibroblasts, and we studied the transcriptional response following exposure to selenocystine on the gene transcription level in keloids by the use of an array gene chip. Functional genomic approaches have become a new strategy for biological studies, generally by use of DNA microarray systems. Such DNA microarray technologies can be used to monitor unclear gene interactions in a global way in human cells in response to therapeutical treatment.
Our results demonstrated an in vitro anti-proliferative activity of selenocystine in keloid fibroblasts, decreasing keloid tumor potential. Moreover, the DNA microarray system evaluated the differential gene expression patterns of keloid fibroblasts in response to treatment with selenocystine, showing that involvement of several genes, especially those belonging to the cytoskeleton and collagen families are likely to be responsible for susceptibility to selenocystine effects in keloid fibroblasts. Keloids are characterized by an abnormal composition of Extra Cellular Matrix proteins, which include elevated levels of collagen proteins [13] ; these data are consistent with the fact that keloid lesions are extremely abundant; in fact it is reported that many genes, encoding general extracellular matrix proteins such as the collagen family, are strongly up-regulated in keloid lesions [14] .
Our results demonstrated that DNA microarray system can be employed to evaluate the differential gene expression patterns of keloid fibroblasts in response to selenocystine exposure to a better understanding of the genes involved in the treatment which may potentially lead to the development of effective therapeutic treatments.
Materials and methods

Cell cultures and treatment
Fresh tissues were obtained from skin lesions of 16 patients with keloids for establishing the primary cell cultures. Fibroblasts from keloids were isolated from samples following the same method established by Lim et al. [15] . All experiments used cells between the second and third passage. No morphological and biochemical differences were found with the passage. Fibroblast cells were grown to confluence in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS), 10 μg/mL streptomycin, and 50 IU/mL penicillin in 5% carbon dioxide at 37°C.
From the second passage treatment time course experiments were set up for 24, 48, and 72 h without serum starvation, adding different concentrations of selenocystine (10, 20, 40 μM respectively) dissolved in 0.5 N HCl.
Phase contrast microscopy
Phase contrast images of control and treated cells were generated with the aid of a Zeiss Axiovert 40 CFL inverted microscope equipped with a Canon Power Shot G6 digital camera.
Cell viability analysis
To assess the cell metabolic activity, the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay was carried out using a modified method described by Li et al. [16] . Briefly, 5 × 10 4 cells were seeded in each well containing 100 μl RPMI-1640 medium supplemented with 10% fetal bovine serum in a 96-well plate. After incubation for 24, 48 h and 72 h respectively 50 μl MTT (SigmaAldrich, St. Louis, USA) (5 mg/ml stock solution) was added and incubated at 37°C for another 4 h. Then 0.2 ml of DMSO was added to stop the reactions. The absorbance of each well was determined spectrophotometrically at 490 nm by a microplate reader (Bio-Tek, Rockville, USA). All results shown are mean ± SD of at least three separate experiments, measuring each parameter by triplicate (n = 3). Statistical significant differences were tested by one way analysis of variance (ANOVA), and, when the F value was significant, by Student-Newman-Keul's test. P value less than 0.05 (*) was considered statistically significant.
RNA isolation
Total RNA of fibroblasts from untreated keloids and treated keloids was extracted with NucleoSpin RNA II (Macherey-Nagel) according to the manufacturer's instructions. A DNase I treatment was applied to remove traces of contaminating DNA. Good-quality messenger RNA is an essential prerequisite for the high throughput messenger RNA profiling; care was taken to exclude cell cultures with degraded RNA or poor quality. RNA quality and quantity was checked for all the samples before proceeding to all the analysis. Quality of total RNA was checked using Agilent 2100 Bioanalyzer platform (Agilent Technologies).
Microarray processing and data extraction
1 μg of each total RNA sample was used. To produce Cy3-labeled cRNA, the RNA samples were amplified and labeled using the Agilent Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies) following the manufacturer's protocol.
Yields of cRNA and dye-incorporation rate were measured with ND-1000 Spectrophotometer (NanoDrop Technologies). The hybridization procedure was performed using the Agilent Gene Expression Hybridization kit. Briefly, 1.65 μg of Cy3-labeled fragmented cRNA in hybridization buffer was hybridized overnight to Whole Human Genome Oligo Microarrays 4x44K (Agilent Technologies).
Microarray hybridization and washing were performed using reagents and instruments (hybridization chambers and rotating oven) as indicated by the manufacturer (Agilent Technologies). Microarrays were scanned using Microarray Scanner System (Agilent Technologies).
Microarray data analysis
The 20 CEL files generated by the Agilent Microarray Suite version 5.0 (MAS 5.0; Agilent) were converted into DCP files using dChip V1.3 software (for more information, access the following Web site: http:// www.dchip.org).
The Agilent Features Extraction Software (FES) was used to read out and process the microarray image files. FES output data files were further analyzed using the Rosetta Resolver gene expression data analysis system (Rosetta Biosoftware).
The DCP files were normalized, and raw gene expression data were generated using model-based analysis of the dChip system.20. For comparison of global gene expression profiles between two sample sets (e.g., control vs CJD samples), Significance Analysis of Microarray (SAM) software (for more information, access the following Web site: http:// www.stat.stanford.edu/_tibs/SAM/index.html) was used with two-class response analysis. SAM is a statistical method adapted specifically for multiple comparison issues in the context of microarray data, and it has been shown to be more accurate than the calculation of fold change.21 SAM identified genes with statistically significant changes in expression by assimilating a set of gene-specific t tests. Each gene, i, is assigned a score, d(i), representing the relative difference of this gene. The d(i) score is generated based on the ratio of the change in expression of gene i in different states (e.g, in control cases and patients) relative to the standard deviation of repeated measurements. SAM also estimates the percentage of genes identified by chance, based on permutations of the measurements for each gene. In this study, genes were considered differentially expressed if they changed more than 2-fold (see Results) with a p b 0.01. For hierarchical clustering, gene expression data generated by dChip software were log transformed, median centered, and analyzed for clustering according to Eisen and colleagues [17] .
Gene function analysis was performed by using the gene ontology mining tool of NetAffx,23 which is based on the Gene Ontology database (http://www.geneontology.org). Specification of the many gene annotations was also supplemented by further online database searches.
Quantitative reverse transcription-PCR (real-time RT-PCR)
To confirm the expression patterns of eight top candidate genes (COL15A1, COL5A3, COL3A1, COL1A1, COL6A3 and FLRT3), most down-expressed in keloid fibroblasts in response to selenocystine exposure, we performed a quantitative RT-PCR using the comparative C t method. Transcript levels of the target genes were normalized to β-actin (the internal control) after correcting for differences in amplification efficiencies. RT-PCR reactions (n=3) were performed for each gene of interest using a quantitative real-time Light-Cycler (Roche). All genes investigated have previously been identified and sequences were available in GenBank. Primers for qRT-PCR analysis were designed using the Primer3 program (http://www.bioinformatic.nl/cgi-bin/primer3plus/ primer3plus.cgi).
The final PCR reactions contained: 0.4 μM of each primer; 0.25 × SYBR Green (Invitrogen); 4 mM MgCl 2 and as template 5 μl of cDNA reverse transcribed from a standardized amount of total RNA (0.3 μg). qRT-PCR was performed using Hotstart Taq polymerase (Qiagen) in a final volume of 20 μl. All quantitative reactions were subjected to: 95°C for 15 min followed by 45 cycles at 94°C for 15 s, 59°C 15 s and 72°C 15 s. Melting curve analysis was applied to all reactions to ensure homogeneity of the reaction product. In addition, the amplicon size was checked electrophoretically for each primer set and subsequent sequencing revealed that it corresponded to the human COL15A1, COL5A3, COL3A1, COL1A1, COL6A3 and FLRT3 transcripts respectively, thus verifying the identity of the genes. Potential contamination was assessed by including non-reverse transcribed total RNA (genomic DNA contamination) and controls without template, observing no products in these reactions.
Results
Treatment of keloid fibroblasts with selenocystine
We determined the selenocystine concentrations at 10, 20, and 40 μM (using similar treatment times at 24, 48 and 72) that resulted in a reduction in the number of viable cells of approximately 50% compared to un-treated keloids using MTT test (Fig. 1) . 20 μM selenocystine after 48 h was the chosen condition. Using this approach, we ensured that a sufficient number of viable cells could remain as a source of mRNA for microarray analyses.
Selenocystine impairs in vitro keloid fibroblast development and cytoskeleton
A common property that can impair both cell proliferation and migration, with no evidence of cell death, is associated with disorganization of actin cytoskeleton [18] [19] [20] .
The behavior of keloid fibroblasts over the 72 h period of treatment with 20 μM selenocystine was monitored by phase-contrast microscopy and high enlargement pictures analyzed. As illustrated in Fig. 2 at 48 h of incubation time, comparing treated to untreated keloid fibroblasts morphological changes are evident that strongly suggest alterations in the cytoskeleton organization.
We hypothesized cytostatic effects for selenocystine, rather than cytotoxic ones, due to impairment of cell migration, differentiation and development, and cytoskeleton damage.
Transcriptomic response to treatment with selenocystine: microarray data analysis
Comparing the normalized signal intensities obtained for the untreated vs treated fibroblast keloid cells, in response to the treatment with selenocystine, using a fold change cut off of 2 (pb 0.01), the expression of 8288 genes was significantly higher, while the expression of 8605 genes was lower (Fig. 3) .
A summary of our key findings on selected differentially expressed genes in treated keloid cells is shown in Fig. 4 , Tables 1 and 2 . For upregulated and down-regulated genes, we considered only those with at least a 2-fold change in the level of RNA transcript expression in three independent experiments. Differences in expression were calculated by dividing the signal intensity values of genes from keloid-treated cells by intensity values of genes from keloid-untreated cells (control).
After purging the redundant transcripts for the identical genes, we were able to identify a group of top-ranking treated keloid fibroblasts differentially expressed genes from within the initial list of 16,000 genes ( Fig. 3) , which have known or suspected roles (direct or indirect) in influencing keloid inhibiting proliferation. Only the biological processes with groups containing genes with significantly changed expression were considered relevant (Fig. 4) .
Selected genes from these groups can be viewed in Tables 1 and 2 ; these mainly include gene products related to the cell cycle, cell adhesion and cytoskeletal organization. Interestingly, the expression of various genes involved in cell differentiation and development, cytoskeleton organization, cell adhesion and extra cellular matrix was down-regulated. Furthermore, among the up-regulated genes, many were known to be involved in transcription and cell death.
These gene sets with significantly altered expression are described in more detail below. 
Decreased expression of genes involved in cell differentiation, and development, cytoskeleton, cell migration, and cell adhesion
A tumor can be viewed as an aberrant organ initiated by a cancer stem cell that undergoes processes analogous to the self-renewal and differentiation of normal stem cells [21] . Therefore, understanding differentiation may ultimately lead to the development of differentiation therapy, which is directed toward the reversal of the maturation arrest, thus allowing the cancer cells to differentiate and die eventually [22] .
Our array data showed down-regulation of genes involved in cell differentiation as ITGAV, MAPK12, and a development as FZD4, ITGB1BP2, ELAVL1, KIRREL3, CSNK2A1, and CDON.
In tumor induction and progression, the elements of the actin cytoskeleton (or the microfilament system), adhesion and tissue invasion have crucial roles in integrating and propagating signaling circuits and dynamic morphological alterations. We found downregulation of genes involved in cytoskeleton as TPM3, RABGAP1, FSCN1, CAMK2N1, FILIP1L, TBCC, KIF20A, ABRA, ACTN4, and KIF6, migration as TPM3, NUDT6, and BBS2, and cell adhesion as PCDHB6, NDN, SNED1, CDON, CCL2, PTK7, and ITGAV.
Extra cellular matrix gene expression
Our array data showed that extra cellular matrix genes, markers of keloid progression, were down-regulated, such as EMILIN1 and the members of the collagen gene family, as collagen types XV, I, X, XII, XIV, IV, V, III, and VI. The down-regulation of seven top collagen genes and fibronectin, following selenocystine exposure, was confirmed by a quantitative real time PCR assay (Fig. 5 ).
Increased expression of genes involved in transcription and protein folding/modification, and kinase/phosphatase signaling
A differential up-expression of transcription factors was characterized following selenocystine treatment, such as several ZN finger transcription factors, protein folding/modification genes as DPH3, MTMR3, and BRPF3, and kinase/phosphatase signaling: PRKAG2, STK17B, PLK3, and DCLK2, usually more expressed in sensitive tumors, in contrast to resistant tumors.
Cell death gene expression
Our array data showed that selenocystine treatment selectively downregulated the expression of cell death related genes, as SMAD7, BCL2L11, UNC5B, DEDD2, and GADD45G. Previous data demonstrate that members of the Gadd45 gene family are important for anti-tumor immune responses [23] .
Gadd45 proteins cooperate in the activation of S and G2-M checkpoints following exposure of cells to UV irradiation and other genotoxic stresses, producing growth arrest and apoptosis [24, 25] . Some of these genes differentially expressed in our list or from the same families have been shown previously to be involved with chemotherapy response [26] [27] [28] .
Discussion
Global expression profiling in selenocystine treated keloid fibroblasts allowed us to understand the distinct expression patterns underlying the mechanism of action of this compound in keloid fibroblasts.
Keloids are dermal tumors in which an overabundance of extracellular matrix is produced during the wound healing process [29] . They appear as raised, red and inflexible scar tissue that is itchy and painful. The lesions expand over the boundaries of the initial injury site through the rapid proliferation of fibroblast-like cells [30] . Thus, keloids represent a derailment of the protective wound-healing process. Proliferation of fibroblastic cells is one of the typical characteristics of keloid lesions. Keloids resist all clinical therapies and often recur, which means that the quality of life of many patients is seriously compromised by keloid disease. The lack of relevant animal models hampers efforts to establish the etiology of keloid disease, and many attempts to explore treatment modalities have proved unsuccessful.
Furthermore, tumorigenesis is characterized by increased motile activity, increased rate of cell proliferation and removal of growth inhibiting cell-cell contacts.
Tissue invasion by cancer cells requires the integration of several actin cytoskeleton-dependent processes that include the local modulation of contractile forces and mechano-transduction, the turnover of cell-matrix adhesions and of the associated microfilament system, the locally restricted bifurcation(s) of GTPase signaling, and the generation of specialized, transient adhesions that mediate the focal degradation of the extracellular matrix.
Receptor activation sets up cell motility and migration, and institution of the growth cycle. Increased expression of metalloproteinases allows the spread of malignant cancer cells to other sites in the organism breaking contacts between cells and organ boundaries. Several trans-membrane proteins such as growth factor receptors, adhesion proteins and ion channels are involved, and generate force capacity, with the sub-membranous system of actin microfilaments. Perturbations in redox control of the actin-system in cell motility and migration, actin microfilament formation and its regulation are involved in cancer development [31] . Altered expression of proteins belonging to the MF-system, e.g. profilin, cofilin, tropomyosin, gelsolin, α-actinin, and vinculin, is frequently associated with malignant transformation [32] [33] [34] [35] [36] [37] [38] . Integrins carry out cellmatrix and cell-cell interactions, whereas adhesion via the cadherin family of adhesion proteins is usually intercellular. Cadherin-cadherin interactions link the MF-systems of adjacent cells [39] [40] [41] . 
Transcription
Here, we performed a cDNA microarray analysis of keloid fibroblasts in comparison with normal fibroblasts following exposure to selenocystine, a seleno-amino acid, previously identified as a novel agent with broad-spectrum antitumor activity, to explore novel treatment modalities for keloids. So far, there is no clinical study on its effect on keloid fibroblasts. To elucidate the molecular mechanism of selenocystine treatment in keloid fibroblasts, the gene expression patterns in the keloid fibroblasts following selenocystine exposure was analyzed by cDNA microarray strategy.
Carcinogenesis is a multi-step process and selenium's effect can be on genes related to early events (i.e. initiation phase); genes related to Phase I and Phase II enzymes involved in the metabolic activation of selenocystine employed in this study as well as on genes that are critical in the post-initiation phase of carcinogenesis (genes related to cell cycle, proliferation and apoptosis). This suggests impaired cell proliferation in treated keloid fibroblasts. Reduced cell proliferation could explain a decreased susceptibility of these blasts to treatment.
Comparison of our data with those published by other authors [14] showed the molecular mechanisms that may explain another side of selenocystine treatment response. It is known that keloids are extremely abundant in extracellular matrix; in fact it is reported [14] the up-regulation of genes encoding extracellular matrix proteins; in addition to the previously identified collagen types I and VI.
Remarkably, genes encoding general extracellular matrix proteins, including collagen types V, XV and XVI and fibronectin, have also been found to be strongly upregulated in the keloids. While collagen type V is a fibrillar collagen that widely distributes in extracelluar matrix of many types of tissues, a recent report indicated that expression of this collagen is strongly up-regulated during mouse bone development [42] . Interestingly, COL15A1 gene, encoding the alpha chain of type XV collagen, is a member of the FACIT collagen family (fibril-associated collagens with interrupted helices), described as being expressed in the basement membrane to underlying connective tissue stroma. Type XV collagen has a wide tissue distribution but the strongest expression is localized to basement membrane zones so it may function to adhere basement membranes to underlying connective tissue stroma. In our array experiments, it is noteworthy that, following selenocystine treatment, the gene-expression signatures associated with extracellular matrix was significantly down-regulated in keloid fibroblasts. Collagen types XV, I, X, XII, XIV, IV, V, III, and VI genes have been downregulated following selenocystine treatment such as laminin 3 and 4, matrix metallopeptidase 13 and EMILIN1.
EMILIN1, an extracellular matrix protein with adhesive properties [43, 44] , at first described as an IFN-induced gene but however contribute to combating cellular stress independent of the IFN system [45] , is up-regulated in responsive tumors. These results, confirmed by quantitative real time PCR assay (Fig. 5) , imply that selenocystine treatment may be able to attenuate the expression of genes related to the extracellular matrix generally upregulated in keloid fibroblasts.
In conclusion, modulation of genes involved in extracellular matrix cell proliferation and cell death provide a mechanistic basis for keloid prevention in this cell model system. 
